What is the global market size of Breast Cancer Liquid Biopsy Market?

Breast Cancer Liquid Biopsy Market size was valued at USD 277 million in 2021 and is poised to grow from USD 417.03 million in 2023 to USD 1746.15 million by 2030, at a CAGR of 22.7% during the forecast period (2023-2030).

Who are the key vendors in the Global Breast Cancer Liquid Biopsy Market?

The global breast cancer liquid biopsy market was witnessing intense competition among key players. Companies in this space were continuously focusing on technological advancements, strategic collaborations, and product innovations to gain a competitive edge. The market was characterized by a diverse range of liquid biopsy solutions aimed at detecting breast cancer-related biomarkers in a non-invasive manner. Additionally, the growing emphasis on early cancer detection and personalized medicine was fueling the demand for liquid biopsy products, driving further competition and market growth. 'Guardant Health - United States', 'Roche Diagnostics - Switzerland', 'Biocept, Inc. - United States', 'Genomic Health (acquired by Exact Sciences) - United States', 'Illumina, Inc. - United States', 'Thermo Fisher Scientific - United States', 'QIAGEN - Germany', 'Myriad Genetics - United States', 'Personal Genome Diagnostics Inc. (PGDx) - United States', 'Bio-Rad Laboratories, Inc. - United States', 'Trovagene, Inc. (acquired by Admera Health) - United States', 'Exosome Diagnostics (acquired by Bio-Techne Corporation) - United States', 'Sysmex Corporation - Japan', 'Natera, Inc. - United States', 'Foundation Medicine (acquired by Roche) - United States', 'GRAIL, Inc. (acquired by Illumina) - United States', 'Menarini Silicon Biosystems - Italy', 'Angle plc - United Kingdom', 'Cynvenio Biosystems, Inc. - United States', 'DiaCarta, Inc. - United States'.

Breast Cancer Liquid Biopsy Market Size

Breast Cancer Liquid Biopsy Market Insights

Breast Cancer Liquid Biopsy Market size was valued at USD 417.03 Million in 2023 and is poised to grow from USD 511.7 Million in 2024 to USD 2628.87 Million by 2032, growing at a CAGR of 22.7% during the forecast period (2025-2032).

The global breast cancer liquid biopsy market has experienced significant growth and innovation in recent years, driven by increasing awareness and adoption of non-invasive diagnostic techniques. The technology's ability to detect tumor-specific genetic mutations, circulating tumor cells, and cell-free DNA provides crucial information for early detection, treatment selection, and monitoring of treatment response. Additionally, ongoing research and development efforts are likely to lead to enhanced sensitivity and specificity of liquid biopsy tests, driving further market expansion.

As the medical community embraces this innovative approach, the global breast cancer liquid biopsy market is expected to experience substantial growth in the coming years. The technology's ability to detect tumor-specific biomarkers, circulating tumor cells (CTCs), and cell-free DNA in blood samples has revolutionized cancer diagnostics and treatment monitoring. Moreover, the market has been fueled by ongoing research and development efforts, collaborations between biotech companies and healthcare institutions, and a rising demand for personalized and targeted therapies for breast cancer patients.

US Breast Cancer Liquid Biopsy Market is poised to grow at a sustainable CAGR for the next forecast year.

FAQs

Breast Cancer Liquid Biopsy Market size was valued at USD 417.03 Million in 2023 and is poised to grow from USD 511.7 Million in 2024 to USD 0 Million by 2032, growing at a CAGR of 22.7% during the forecast period (2025-2032).

The global breast cancer liquid biopsy market was witnessing intense competition among key players. Companies in this space were continuously focusing on technological advancements, strategic collaborations, and product innovations to gain a competitive edge. The market was characterized by a diverse range of liquid biopsy solutions aimed at detecting breast cancer-related biomarkers in a non-invasive manner. Additionally, the growing emphasis on early cancer detection and personalized medicine was fueling the demand for liquid biopsy products, driving further competition and market growth. 'F. Hoffmann-La Roche Ltd ', 'Bio-Rad Laboratories Inc. ', 'Illumina Inc. ', 'Guardant Health Inc. ', 'QIAGEN ', 'Biocept Inc. ', 'Thermo Fisher Scientific ', 'Adaptive Biotechnologies ', 'Myriad Genetics ', 'Fluxion Biosciences Inc. ', 'Biodesix ', 'Exosome Diagnostics Inc. ', 'Epic Sciences ', 'PapGene ', 'Pathway Genomics (OME Care) ', 'Agena Bioscience ', 'MDxHealth ', 'Janssen Diagnostics ', 'Abbott '

The increasing adoption of liquid biopsy techniques is a significant driver in the global breast cancer liquid biopsy market. Compared to traditional tissue biopsies, liquid biopsies allow for the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomarkers present in blood samples, enabling healthcare professionals to make more informed treatment decisions. Additionally, liquid biopsy has the potential to identify resistance mutations and minimal residual disease, which can aid in personalized treatment strategies, leading to improved patient outcomes and reduced healthcare costs.

There was a growing emphasis on non-invasive diagnostic methods, such as liquid biopsies, for early detection and monitoring of breast cancer.

North America led the way with a strong presence of key market players, advanced healthcare infrastructure, and growing adoption of liquid biopsy technologies. Europe demonstrated significant growth due to increased awareness, supportive government initiatives, and rising research and development activities. The Asia-Pacific region exhibited substantial potential, driven by a large patient pool, expanding healthcare expenditure, and increasing focus on personalized medicine. Latin America and the Middle East/Africa regions also experienced a gradual uptick in liquid biopsy adoption, with improving healthcare facilities and a greater emphasis on cancer diagnostics.